Analysis of the Relationship of Cognitive Impairment and Functional Impairment in Mild Alzheimer’s Disease in EXPEDITION 3
暂无分享,去创建一个
E. Siemers | J. Cummings | R. Mohs | P. Aisen | H. Liu-Seifert | K. Sundell | M. Mynderse
[1] M. Mintun,et al. Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease , 2018, The New England journal of medicine.
[2] Roy W Jones,et al. On the path to 2025: understanding the Alzheimer’s disease continuum , 2017, Alzheimer's Research & Therapy.
[3] C. Jack,et al. Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria , 2016, Alzheimer's & Dementia.
[4] E. Siemers,et al. Correlation between Cognition and Function across the Spectrum of Alzheimer's Disease. , 2016, The journal of prevention of Alzheimer's disease.
[5] Karen L. Price,et al. Cognitive and functional decline and their relationship in patients with mild Alzheimer's dementia. , 2014, Journal of Alzheimer's disease : JAD.
[6] E. Siemers,et al. COGNITIVE IMPAIRMENT PRECEDES AND PREDICTS FUNCTIONAL IMPAIRMENT IN MILD ALZHEIMER'S DISEASE , 2014, Alzheimer's & Dementia.
[7] E. Siemers,et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. , 2014, The New England journal of medicine.
[8] Y. Stern,et al. Cognitive Declines Precede and Predict Functional Declines in Aging and Alzheimer’s Disease , 2013, PloS one.
[9] Nick C Fox,et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[10] J. Morris,et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[11] Charles Duyckaerts,et al. National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach , 2011, Acta Neuropathologica.
[12] R. Petersen,et al. Development of Cognitive Instruments for Use in Clinical Trials of Antidementia Drugs: Additions to the Alzheimer's Disease Assessment Scale That Broaden Its Scope , 1997, Alzheimer disease and associated disorders.
[13] M. Sano,et al. An Inventory to Assess Activities of Daily Living for Clinical Trials in Alzheimer's Disease , 1997, Alzheimer disease and associated disorders.